A phase 1a/1b, open-label, dose-escalation and dose-expansion study of the anti-CTLA-4 monoclonal antibody CS1002 as monotherapy and in combination with anti-PD-1 monoclonal antibody CS1003 in subjects with advanced solid tumors

  • Moore, Maggie (Primary Chief Investigator (PCI))
  • Hawkins, Cheryl-Ann (Project Manager)

Project: Research

Project Details

Effective start/end date2/06/2031/12/23


  • Medical oncology
  • Monoclonal Antibody
  • Clinical trial